Effects of autologous serum on TREM2 and APOE in a personalized monocyte-derived macrophage assay of late-onset Alzheimer’s patients

Table 2 Modulation of TREM2 and APOE levels in short- and long-term differentiated Mo-MФs in autologous serum (AS)

	SHORT-TERM							LONG-TERM
CO (n = 16)
*Gene/ Protein**	Friedman statistic	p-value	Dunn´s multiple comparison tests					Friedman statistic	p-value	Dunn´s multiple comparison tests
*Gene/ Protein**	Friedman statistic	p-value	M1 vs. M2		M1 vs. M0		M2 vs. M0	Friedman statistic	p-value	M1 vs. M2		M1 vs. M0		M2 vs. M0
TREM2	16.63	0.0002	0.0080		0.0003		> 0.9999	21.5	< 0.0001	< 0.0001		0.2313		0.0140
sTREM2	9.875	0.0072	0.0647		0.0080		> 0.9999	17.38	0.0002	0.0140		0.0001		0.6478
APOE	0.1250	0.9394	> 0.9999		> 0.9999		> 0.9999	0.875	0.6456	> 0.9999		> 0.9999		> 0.9999
AD (n = 21)
TREM2	22.57	< 0.0001	< 0.0001	0.0036		0.4947		11.81	0.0027	0.0021	0.0923		0.6511
sTREM2	6	0.0498	0.1922	0.0619		> 0.9999		20.86	< 0.0001	0.0006	< 0.0001		> 0.9999
APOE	0.2857	0.8669	> 0.9999	> 0.9999		> 0.9999		2.571	0.2765	0.4947	> 0.9999		0.4947

qPCR products* (in italic) and proteins calculated using Friedman ANOVA Test with significance values adjusted by the Bonferroni correction (p < 0.0167) for Dunn´s multiple comparison tests for all measured markers in M1. M2. and M0 after short- and long-term differentiation. TREM2- triggering receptor expressed on myeloid cells 2; sTREM2- soluble triggering receptor expressed on myeloid cells 2; APOE- apolipoprotein E

ISSN: 1742-4933